On December 30, 2015, the board of directors of OncBioMune Pharmaceuticals, Inc. elected Daniel S. Hoverman as a member of the Board. Mr. Hoverman is a Director and senior member in Houlihan Lokey, Inc.'s Mergers & Acquisitions Group, where he advises companies on sale, financing and other strategic corporate transactions. Prior to joining Houlihan Lokey in 2010, Mr. Hoverman was a Director with Credit Suisse in Hong Kong in the Office of the General Counsel, and a Director with UBS in New York in the Equity Capital Markets Group.